Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BLB-201 RSV Vaccine in Infants and Children
NCT05655182Phase 2Recruiting
- Sponsor
- Blue Lake Biotechnology
- Start
- Mar 2023
- Primary completion
- Dec 2028
- Modality
- Viral Vectors, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of BLB-201 in respiratory syncytial virus infection (RSV) (10 arms), sponsored by Blue Lake Biotechnology. Primary endpoints: Solicited Adverse Events and Unsolicited Adverse Events. Started Mar 2023; status: recruiting.
02
Drugs
BLB-201
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT05655182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05655182.